We are live on ! Find out more
PDSB icon

PDS Biotechnology
PDSB

21 hedge funds and large institutions have $1.72M invested in PDS Biotechnology in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

309% more capital inflows, than outflows

Capital inflows: $368K | Capital outflows: $90K

0.93% more ownership

Funds ownership: 8.91% → 9.84% (+0.93%)

0% more funds holding

Funds holding: 21 → 21 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

Holders
21
Holders Change
–
Holders Change %
0%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RegentAtlantic Capital
RegentAtlantic Capital
New Jersey
+$106K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$88.8K
3
Iron Gate Global Advisors
Iron Gate Global Advisors
Utah
+$85.2K
4
Renaissance Technologies
Renaissance Technologies
New York
+$76.2K
5
Victory Capital Management
Victory Capital Management
Texas
+$4.48K

Top Sellers

Rank Fund Capital Flow
1
Samsara BioCapital
Samsara BioCapital
California
-$55K
2
Panagora Asset Management
Panagora Asset Management
Massachusetts
-$24K
3
UBS Group
UBS Group
Switzerland
-$9K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$2K

PDSB Hedge Fund Activity: Q3 2019 in Review

21 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q3 2019, worth a combined $1.72M — down 38% from $2.76M a quarter earlier.

Fund positioning in PDSB was balanced in Q3 2019: 4 funds opened new positions, 4 closed out, 4 added to existing stakes and 0 trimmed.

The largest buyer was RegentAtlantic Capital, opening a new position worth an estimated $106K. The largest seller was Samsara BioCapital, exiting entirely with an estimated $55K sold.

  • 21 institutional investors held PDS Biotechnology (PDSB) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $1.72M of PDS Biotechnology stock for Q3 2019, down 38% quarter-over-quarter.
  • 4 funds opened new PDS Biotechnology positions in Q3 2019 and 4 closed out, a net change of 0 holders.
  • The largest PDS Biotechnology buyer in Q3 2019 was RegentAtlantic Capital, an estimated $106K added.
  • The largest PDS Biotechnology seller in Q3 2019 was Samsara BioCapital, an estimated $55K sold.

Based on aggregated 13F filings for Q3 2019.